Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood
Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at...
Gespeichert in:
Veröffentlicht in: | Medical and pediatric oncology 1993, Vol.21 (2), p.103-110 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 110 |
---|---|
container_issue | 2 |
container_start_page | 103 |
container_title | Medical and pediatric oncology |
container_volume | 21 |
creator | Toogood, Ian R. G. Tiedemann, Karin Stevens, Michael Smith, Peter J. |
description | Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only.
There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation.
Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/mpo.2950210205 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mpo_2950210205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MPO2950210205</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</originalsourceid><addsrcrecordid>eNqFkMtPGzEQxi1URAP0yq2SD71u8GO9Xh8pghQUHqqomps160fjso5Xuxto_vu6ShTUE6eZ0XzfPH4InVEypYSw89ilKVOCMEoYEQdoQomqCkXp4gOaEKLqggrOPqLjYfhNcq1kfYSO6pLzSooJMlfeOzOGF4fjuh1DAb_casRm6WIal66HboN96jHYF1gZZzE0NsWwgha3m9gtUwQMK4uvL77iOcetWz-7GAAnn2eE1i5Tsqfo0EM7uE-7eIJ-XF89XX4r5g-zm8uLeWE4Y6KglWtMpYz0THIiSpCiIpQBNdKoUjZNIygXKpegBDVGgGlYXZf5v9JbK_kJmm7nmj4NQ--87voQod9oSvQ_WDrD0m-wsuHz1tCtm-jsXr6jk_tfdn0YDLS-zwjCsJeVopKM0ixTW9lraN3mnaX67vHhvxOKrTcMo_uz90L_rCvJpdA_72c5W3yvH2e3esH_ArUFkcM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</creator><creatorcontrib>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</creatorcontrib><description>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only.
There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation.
Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950210205</identifier><identifier>PMID: 8433675</identifier><identifier>CODEN: MPONDB</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject><![CDATA[Abdominal Neoplasms - drug therapy ; Adolescent ; advanced non-Hodgkin′s lymphoma ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asparaginase - administration & dosage ; Asparaginase - adverse effects ; B-cell leukaemia ; Biological and medical sciences ; Burkitt Lymphoma - drug therapy ; Chemotherapy ; Child ; Child, Preschool ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Cytarabine - administration & dosage ; Cytarabine - adverse effects ; diffuse undifferentiated histology ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Female ; Humans ; Infant ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Neoplasm Recurrence, Local ; Neoplasms, Multiple Primary - drug therapy ; Pharmacology. Drug treatments ; Prednisolone - administration & dosage ; Prednisolone - adverse effects ; Remission Induction ; Retrospective Studies ; Survival Rate ; Teniposide - administration & dosage ; Teniposide - adverse effects ; treatment ; Vincristine - administration & dosage ; Vincristine - adverse effects]]></subject><ispartof>Medical and pediatric oncology, 1993, Vol.21 (2), p.103-110</ispartof><rights>Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1993 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</citedby><cites>FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950210205$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950210205$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4567211$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8433675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toogood, Ian R. G.</creatorcontrib><creatorcontrib>Tiedemann, Karin</creatorcontrib><creatorcontrib>Stevens, Michael</creatorcontrib><creatorcontrib>Smith, Peter J.</creatorcontrib><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only.
There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation.
Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</description><subject>Abdominal Neoplasms - drug therapy</subject><subject>Adolescent</subject><subject>advanced non-Hodgkin′s lymphoma</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asparaginase - administration & dosage</subject><subject>Asparaginase - adverse effects</subject><subject>B-cell leukaemia</subject><subject>Biological and medical sciences</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cytarabine - administration & dosage</subject><subject>Cytarabine - adverse effects</subject><subject>diffuse undifferentiated histology</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasms, Multiple Primary - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone - administration & dosage</subject><subject>Prednisolone - adverse effects</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Teniposide - administration & dosage</subject><subject>Teniposide - adverse effects</subject><subject>treatment</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtPGzEQxi1URAP0yq2SD71u8GO9Xh8pghQUHqqomps160fjso5Xuxto_vu6ShTUE6eZ0XzfPH4InVEypYSw89ilKVOCMEoYEQdoQomqCkXp4gOaEKLqggrOPqLjYfhNcq1kfYSO6pLzSooJMlfeOzOGF4fjuh1DAb_casRm6WIal66HboN96jHYF1gZZzE0NsWwgha3m9gtUwQMK4uvL77iOcetWz-7GAAnn2eE1i5Tsqfo0EM7uE-7eIJ-XF89XX4r5g-zm8uLeWE4Y6KglWtMpYz0THIiSpCiIpQBNdKoUjZNIygXKpegBDVGgGlYXZf5v9JbK_kJmm7nmj4NQ--87voQod9oSvQ_WDrD0m-wsuHz1tCtm-jsXr6jk_tfdn0YDLS-zwjCsJeVopKM0ixTW9lraN3mnaX67vHhvxOKrTcMo_uz90L_rCvJpdA_72c5W3yvH2e3esH_ArUFkcM</recordid><startdate>1993</startdate><enddate>1993</enddate><creator>Toogood, Ian R. G.</creator><creator>Tiedemann, Karin</creator><creator>Stevens, Michael</creator><creator>Smith, Peter J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1993</creationdate><title>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</title><author>Toogood, Ian R. G. ; Tiedemann, Karin ; Stevens, Michael ; Smith, Peter J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3225-16ebc69c7f273054a756012a1c7c947bbb513591c7a951cc5acb28841534fdd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Abdominal Neoplasms - drug therapy</topic><topic>Adolescent</topic><topic>advanced non-Hodgkin′s lymphoma</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asparaginase - administration & dosage</topic><topic>Asparaginase - adverse effects</topic><topic>B-cell leukaemia</topic><topic>Biological and medical sciences</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cytarabine - administration & dosage</topic><topic>Cytarabine - adverse effects</topic><topic>diffuse undifferentiated histology</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasms, Multiple Primary - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone - administration & dosage</topic><topic>Prednisolone - adverse effects</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Teniposide - administration & dosage</topic><topic>Teniposide - adverse effects</topic><topic>treatment</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Toogood, Ian R. G.</creatorcontrib><creatorcontrib>Tiedemann, Karin</creatorcontrib><creatorcontrib>Stevens, Michael</creatorcontrib><creatorcontrib>Smith, Peter J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toogood, Ian R. G.</au><au>Tiedemann, Karin</au><au>Stevens, Michael</au><au>Smith, Peter J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1993</date><risdate>1993</risdate><volume>21</volume><issue>2</issue><spage>103</spage><epage>110</epage><pages>103-110</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><coden>MPONDB</coden><abstract>Between June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only.
There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation.
Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8433675</pmid><doi>10.1002/mpo.2950210205</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0098-1532 |
ispartof | Medical and pediatric oncology, 1993, Vol.21 (2), p.103-110 |
issn | 0098-1532 1096-911X |
language | eng |
recordid | cdi_crossref_primary_10_1002_mpo_2950210205 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Abdominal Neoplasms - drug therapy Adolescent advanced non-Hodgkin′s lymphoma Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asparaginase - administration & dosage Asparaginase - adverse effects B-cell leukaemia Biological and medical sciences Burkitt Lymphoma - drug therapy Chemotherapy Child Child, Preschool Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Cytarabine - administration & dosage Cytarabine - adverse effects diffuse undifferentiated histology Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Humans Infant Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Methotrexate - administration & dosage Methotrexate - adverse effects Neoplasm Recurrence, Local Neoplasms, Multiple Primary - drug therapy Pharmacology. Drug treatments Prednisolone - administration & dosage Prednisolone - adverse effects Remission Induction Retrospective Studies Survival Rate Teniposide - administration & dosage Teniposide - adverse effects treatment Vincristine - administration & dosage Vincristine - adverse effects |
title | Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T11%3A38%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20multi-agent%20chemotherapy%20for%20advanced%20abdominal%20lymphoma%20and%20FAB%20L3%20leukemia%20of%20childhood&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Toogood,%20Ian%20R.%20G.&rft.date=1993&rft.volume=21&rft.issue=2&rft.spage=103&rft.epage=110&rft.pages=103-110&rft.issn=0098-1532&rft.eissn=1096-911X&rft.coden=MPONDB&rft_id=info:doi/10.1002/mpo.2950210205&rft_dat=%3Cwiley_cross%3EMPO2950210205%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8433675&rfr_iscdi=true |